Delayed xenograft rejection in the concordant hamster heart into Lewis rat model. 1996

A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
Section of Transplantation, Department of General Surgery, Rush Medical College, Chicago, Illinois 60612, USA.

The inability to provide an adequate supply of human organs for clinical transplantation has created a strong interest in the use of nonhuman, especially nonprimate, organs. The first biological obstacle confronting such discordant transplantations is a series of violent reactions that result in hyperacute rejection of the xenograft. Significant advances in controlling hyperacute rejection have been achieved recently through the generation of transgenic pig donors bearing human complement regulatory proteins. However, when hyperacute rejection is averted, the xenografts are rejected in 2-70 days in spite of high-dose immunosuppression, by a process collectively termed delayed xenograft rejection. Delayed xenograft rejection is characterized by a refractoriness to conventional immunosuppression, extensive xenoreactive antibody deposition, and cellular infiltration that is dominated by macrophages. We have examined the features of extended host and graft response in the concordant hamster-to-rat xenotransplant model, where such features have historically been obscured by early graft destruction. Hamster hearts transplanted into rats do not encounter hyperacute rejection but are rejected within 3-4 days when xenoreactive antibody titers rise exponentially to levels that elicit a classical antibody- and complement-mediated acute xenograft rejection. We have successfully blocked acute xenograft rejection by a combination of immunosuppressive agents, leflunomide, and cyclosporine. Stopping the immunosuppression resulted in graft rejection that is histologically characterized by extensive xenoreactive antibody deposition and cellular infiltration that is predominantly composed of macrophages. We have noted the similarities between the histopathology of rejection of long-surviving concordant xenografts and that described for discordant xenografts and refer to the process of rejection of concordant grafts that have escaped acute xenograft rejection, delayed xenograft rejection.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000077339 Leflunomide An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS. Arava,HWA 486,HWA-486,N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide,SU101,HWA486
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
January 1996, Surgery today,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
October 1990, Transplantation proceedings,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
January 2017, Transplantation proceedings,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
September 1996, Transplant immunology,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
January 1999, Transplantation proceedings,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
October 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
August 1996, Immunology today,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
January 1997, World journal of surgery,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
February 1995, Transplantation proceedings,
A S Chong, and J Shen, and F Xiao, and L Blinder, and L Wei, and H Sankary, and P Foster, and J Williams
June 1990, Transplantation proceedings,
Copied contents to your clipboard!